Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A1 | P43005 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PTPRC | P08575 | 3/20 | 0.34 |
| ▸ | PTPN13 | Q12923 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | AKT1 | P31749 | 1/20 | 0.33 |
| ▸ | GPR3 | P46089 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16933112 | 0.91 | CYP1A2 (0.39) | CYP1A2TSHRCYP2D6KDM4EALDH1A1 | |
| SCHEMBL21175076 | 0.90 | PTPRC (0.35) | CYP1A2TSHRPTPRCKMT2A | |
| SCHEMBL20680359 | 0.89 | PTPRC (0.34) | CYP1A2TSHRPTPRCPTPN13CYP2D6 | |
| SCHEMBL25177898 | 0.88 | CYP1A2 (0.37) | CYP1A2TSHRALDH1A1KMT2AGPR3 | |
| SCHEMBL8893033 | 0.88 | CYP1A2 (0.37) | CYP1A2TSHRKMT2AGPR3 | |
| SCHEMBL8892535 | 0.88 | CYP1A2 (0.37) | CYP1A2TSHRKMT2AGPR3 | |
| SCHEMBL27231102 | 0.87 | PKM (0.39) | CYP1A2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL25182257 | 0.87 | PKM (0.39) | CYP1A2TSHRKDM4EALDH1A1LMNA | |
| SCHEMBL14648233 | 0.86 | CYP1A2 (0.36) | CYP1A2TSHRKDM4EKMT2AGPR3 | |
| SCHEMBL25178735 | 0.86 | CYP1A2 (0.36) | CYP1A2TSHRKDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11325911-B2 | Method for preparing 3-[(4S)-8-bromo-1-methyl-6-(pyridin-2-yl)-4H-imidazo[ 1,2-a][1,4]benzodiazepin-4-yl]-propionic acid methyl ester, and compounds useful in said method | MOEHS IBERICA, S.L. | 2022-05-10 | — | — | US | disclosed |
| US-11236064-B2 | Method for preparing 3-[(3S)-7-bromo-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-[1,4]-benzodiazepin-3-yl] propionic acid methyl ester, and compounds useful in that method | MOEHS IBERICA S.L. (ES) | 2022-02-01 | — | — | US | disclosed |
| EP-3658545-B1 | METHOD FOR PREPARING 3-[(3S)-7-BROMO-2-OXO-5-(PYRIDIN-2-YL)-2,3-DIHYDRO-1H-[1,4]-BENZODIAZEPIN-3-YL]PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN THAT METHOD | MOEHS IBERICA SL (ES) | 2021-08-11 | — | — | EP | disclosed |
| US-20210139452-A1 | METHOD FOR PREPARING 3-[(3S)-7-BROMO-2-OXO-5-(PYRIDIN-2-YL)-2,3-DIHYDRO-1H-[1,4]-BENZODIAZEPIN-3-YL] PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN THAT METHOD | MOEHS IBERICA S.L. (ES) | 2021-05-13 | — | — | US | disclosed |
| EP-3694859-A1 | METHOD FOR PREPARING 3-[(4S)-8-BROMO-1-METHYL-6-(PYRIDIN-2-YL)-4H-IMIDAZO[1,2-A][1,4]BENZODIAZEPIN-4-YL]-PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN SAID METHOD | Moehs Ibérica, S.L. (ES) | 2020-08-19 | — | — | EP | disclosed |
| US-20200239477-A1 | METHOD FOR PREPARING 3-[(4S)-8-BROMO-1-METHYL-6-(PYRIDIN-2-YL)-4H-IMIDAZO[1,2-A][1,4]BENZODIAZEPIN-4-YL]-PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN SAID METHOD | MOEHS IBERICA, S.L. (ES) | 2020-07-30 | — | — | US | disclosed |
| EP-3658545-A1 | METHOD FOR PREPARING 3-[(3S)-7-BROMO-2-OXO-5-(PYRIDIN-2-YL)-2,3-DIHYDRO-1H-[1,4]-BENZODIAZEPIN-3-YL]PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN THAT METHOD | Moehs Ibérica, S.L. (ES) | 2020-06-03 | — | — | EP | disclosed |
| WO-2019072944-A1 | METHOD FOR PREPARING 3-[(4S)-8-BROMO-1-METHYL-6-(PYRIDIN-2-YL)-4H-IMIDAZO[1,2-A][1,4]BENZODIAZEPIN-4-YL]-PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN SAID METHOD | MOEHS IBERICA, S.L. (ES) | 2019-04-18 | — | — | WO | disclosed |
| WO-2019020790-A1 | METHOD FOR PREPARING 3-[(3S)-7-BROMO-2-OXO-5-(PYRIDIN-2-YL)-2,3-DIHYDRO-1H-[1,4]-BENZODIAZEPIN-3-YL] PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN THAT METHOD | MOEHS IBERICA S.L. (ES) | 2019-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139452-A1 | METHOD FOR PREPARING 3-[(3S)-7-BROMO-2-OXO-5-(PYRIDIN-2-YL)-2,3-DIHYDRO-1H-[1,4]-BENZODIAZEPIN-3-YL] PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN THAT METHOD | GABRA3, GRIK5, GABRA6 | SLC1A1 810/4885CYP1A2 572/4885TSHR 2891/4885 |
| US-11236064-B2 | Method for preparing 3-[(3S)-7-bromo-2-oxo-5-(pyridin-2-yl)-2,3-dihydro-1H-[1,4]-benzodiazepin-3-yl] propionic acid methyl ester, and compounds useful in that method | GABRA3, GRIK5, GABRA6 | SLC1A1 810/4885CYP1A2 572/4885TSHR 2891/4885 |
| US-11325911-B2 | Method for preparing 3-[(4S)-8-bromo-1-methyl-6-(pyridin-2-yl)-4H-imidazo[ 1,2-a][1,4]benzodiazepin-4-yl]-propionic acid methyl ester, and compounds useful in said method | GABRA6, GABRA4, GABRA1 | SLC1A1 681/4885CYP1A2 111/4885TSHR 1809/4885 |
| US-20200239477-A1 | METHOD FOR PREPARING 3-[(4S)-8-BROMO-1-METHYL-6-(PYRIDIN-2-YL)-4H-IMIDAZO[1,2-A][1,4]BENZODIAZEPIN-4-YL]-PROPIONIC ACID METHYL ESTER, AND COMPOUNDS USEFUL IN SAID METHOD | GABRA6, GABRA4, GABRA1 | SLC1A1 681/4885CYP1A2 111/4885TSHR 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.